about
A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitisRisk factors for alcoholic liver disease in China.Promotion of mitochondrial energy metabolism during hepatocyte apoptosis in a rat model of acute liver failure.Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure.Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice.Altered expression of zonula occludens-2 precedes increased blood-brain barrier permeability in a murine model of fulminant hepatic failureTIMP-1/MMP-9 imbalance in brain edema in rats with fulminant hepatic failure.A Study of Hepatitis E in Pregnancy: Maternal and Fetal Outcome.Alterations of blood-brain barrier and associated factors in acute liver failure.SOCS3 expression correlates with severity of inflammation in mouse hepatitis virus strain 3-induced acute liver failure and HBV-ACLF.CD69+NK cells contribute to the murine hepatitis virus strain 3-induced murine hepatitis.Suppressor of cytokine signaling 1 protects mice against concanavalin A-induced hepatitis by inhibiting apoptosis.Mir-24 regulates hepatocyte apoptosis via BIM during acute liver failure.Invariant natural killer T-cell-deficient mice display increased CCl₄ -induced hepatitis associated with CXCL1 over-expression and neutrophil infiltration.Activated lymphocytes and high liver expression of IFN-γ are associated with fulminant hepatic failure in patients
P2860
Q34412219-C5912CF1-5F20-4341-9C60-B6805DB252A8Q36076598-922B40EA-06BF-4926-8636-FACD03D3D99CQ36089879-CC3A59B0-D79C-4FA0-A150-533261D7BB2CQ36230503-DE93274D-AB46-4151-9C4A-DD0448143198Q37066630-94D64409-66D0-46DA-9C3D-20D138198877Q37122442-DE452383-2578-4413-815B-094D42174E33Q37155284-0F8A5583-F925-41F1-BCBC-FCE41158B7FBQ37155864-DC40AB76-402D-4A88-B064-1B5346FFCF3EQ37184471-1029D627-18F4-407C-A8E4-F72BA65D5D22Q40532962-356024BD-B2B2-4ACF-98BD-A1EAA625F6E2Q41974315-2701D58E-2B7A-4A15-8B34-87CCF3233726Q42210122-4755B94D-12FA-411C-B0FE-A1A74AF9EA16Q42252959-263F75D6-B174-40B9-9BE5-D1D649030C94Q44857495-6461C5A9-2C26-4367-AF27-CDB8FF9B3E2EQ47125978-80EAAF88-5F1D-4CF8-AC02-85894646BEF6Q54191676-61DF3A86-41AC-436B-8F5C-0CA18F687689Q58848648-510A0AF1-FA6A-438B-99D4-566394D57AC6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Etiology and management of fulminant hepatic failure.
@en
type
label
Etiology and management of fulminant hepatic failure.
@en
prefLabel
Etiology and management of fulminant hepatic failure.
@en
P1476
Etiology and management of fulminant hepatic failure
@en
P2093
Andres T Blei
P2888
P356
10.1007/S11894-003-0008-8
P577
2003-02-01T00:00:00Z